HGP 0904

Drug Profile

HGP 0904

Alternative Names: HGP-0904

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Hypertension

Most Recent Events

  • 01 Jun 2016 Hanmi Pharmaceutical completes a phase III trial in Hypertension and Dyslipidaemia (Combination therapy) in South Korea (NCT02899455)
  • 24 Sep 2014 Preclinical trials in Undefined indication in South Korea (unspecified route)
  • 17 Feb 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top